ClinicalTrials.gg
CompletedNCT01843127Updated Mar 31, 2014

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

A Phase 1 interventional study of Ranolazine and Placebo in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-03-31.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.

Enrollment
8th of 11
24 · median 47
Started
2013
with 1 other
Phase 1
3 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
9 of 11
Gilead Sciences

Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 1, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, 18 to 65 years old, inclusive
  • Documented history of T2DM for ≥5 years
  • (BMI) 20.0 to 40.0 kg/m2, inclusive, at Screening
  • Stable treatment (≥ 12 weeks) with metformin alone, a sulfonylurea alone, a meglitinide alone, or a combination of metformin with either a sulfonylurea or a meglitinide
  • ≥ 7.0% and ≤ 10.5%, inclusive, at Screening
  • Fasting glucose within specific ranges, at Screening and after 14 +/-2 days of wash-out from prior oral anti-diabetic agents
  • Fasting serum C-peptide ≥0.8 ng/mL, at Screening
  • Estimated (eGFR)≥60 mL/min/1.73 m2
  • Ability and willingness to comply with all study procedures during the course of the study, including washout from oral anti-diabetic (OAD) agents approximately 2 weeks prior to Day -2 admission
  • Females of must have a negative pregnancy test at Screening and on Day -2 admission and must agree to use highly effective methods from Screening throughout study participation and for 14 days following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or secondary forms of diabetes
  • History of acute diabetes complications
  • Recent or significant heart conditions
  • Uncontrolled hypertension
  • > 500 msec by at Screening or on Day -2 admission, a personal or family history of QTc prolongation, congenital long QT syndrome, or use of drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
  • History of severe GI disease (e.g., gastroparesis)
  • History of pancreatitis (acute or chronic)
  • Current consumption of > 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
  • Current regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
  • History of substance abuse within 12 months prior to Screening
  • Significant hepatic disease, including, but not limited to, chronic active hepatitis and liver cirrhosis ( Class A, B, or C)
  • History of within 5 years prior to Screening
  • Significant thyroid disease
  • Treatment with selected medications, as indicated in the protocol
  • Prior treatment with open-label ranolazine or known or intolerance to ranolazine or its
  • Known hypersensitivity or intolerance to GLP-1 mimetics
  • Known hypersensitivity or intolerance to acetaminophen
  • (AST) and/or alanine aminotransferase (ALT) > 2.5 X (ULN)
  • Total (TB) > 2 mg/dL
  • \< 12 g/dL (for males) or \< 11 g/dL (for females)
  • Positive for surface antigen
  • Positive for anti- virus antibody
  • Positive for -1 (HIV-1) antibody
  • Positive urine drug screen
  • Positive alcohol test
  • Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of > 500 mL of blood during the 6 weeks prior to Screening
  • Females who are pregnant or breastfeeding
  • Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol, or would compromise the quality of the clinical study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Placebo, Ranolazine, Exenatide

    Drug: Ranolazine · Drug: Placebo · Drug: Exenatide

  • Active comparator
    Ranolazine, Placebo, Exenatide

    Drug: Ranolazine · Drug: Placebo · Drug: Exenatide

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)

    Time frame: Days 5, 10, and 14

Secondary outcomes

  1. Plasma glucose, serum insulin, and serum C-peptide AUCs during the SMT

    Time frame: Days 5, 10, and 14

  2. Collapse under Acetaminophen PK

    Time frame: Days 5 and 10

  3. Area under the plasma acetaminophen concentration-time curve from time 0 to 240 min (AUC0-240 min)

    Time frame: Days 5 and 10

  4. Collapse all under ranolazine pharmacokinetics (PK)

    Time frame: Days 5 and 10

  5. Trough plasma ranolazine concentrations (Ctrough)

    Time frame: Days 5 and 10

  6. Average plasma ranolazine concentration during a dosing interval at steady state (Css,ave)

    Time frame: Days 5 and 10

  7. Area under the plasma ranolazine concentration-time curve over dosing interval (AUCtau)

    Time frame: Days 5 and 10

  8. Apparent elimination half-life (t1/2) of ranolazine

    Time frame: Days 5 and 10

  9. Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.

    Time frame: From Screening to 7 days after the final dose

07

Study locations

3 sites
  • Profil Institute for Clinical Research, Inc.
    Chula Vista, California 91911, United States
  • SeaView Research, Inc
    Miami, Florida 33126, United States
  • Translational Research Institute-Florida Hospital
    Orlando, Florida 32804, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2013
First posted
Apr 30, 2013
Start
Apr 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Mar 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01843127
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 30, 2013
Start date
Apr 2013
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Mar 31, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ranolazine · Exenatide

Start the discussion